Abaloparatide (Tymlos): Uses, Dosing, Efficacy, and How It Compares to Bisphosphonates

What Is Abaloparatide and How Does It Work?

Abaloparatide is a synthetic analog of parathyroid hormone-related peptide (PTHrP) that stimulates new bone formation. Unlike antiresorptive drugs that slow bone breakdown, abaloparatide directly activates osteoblasts to build new bone tissue. The FDA approved it in April 2017 specifically for postmenopausal women with osteoporosis who face a high risk of fracture [1].

The drug binds to the RG conformation of the PTH type 1 receptor (PTH1R), which favors a transient signaling pattern associated with bone formation over bone resorption [2]. This selectivity distinguishes abaloparatide from teriparatide (Forteo), which activates both the RG and R0 conformations of the same receptor. The clinical result is a strong anabolic stimulus with potentially less calcium mobilization from existing bone. Patients self-administer 80 mcg once daily via a prefilled pen injector into the periumbilical region of the abdomen. Treatment is capped at a cumulative lifetime exposure of 24 months due to the osteosarcoma signal observed in rat studies, though no confirmed human cases have been attributed to the drug [3].

The ACTIVE Trial: Primary Efficacy Data

The ACTIVE trial (N=2,463) is the registration study that secured FDA approval for abaloparatide. This was a double-blind, randomized, placebo-controlled study that also included an open-label teriparatide arm.

At 18 months, abaloparatide 80 mcg daily reduced the risk of new morphometric vertebral fractures by 86% compared to placebo (0.58% vs 4.22%; relative risk 0.14 to 95% CI 0.05 to 0.39) [4]. Nonvertebral fractures dropped by 43% (2.7% vs 4.7%; hazard ratio 0.57 to 95% CI 0.32 to 1.00). The teriparatide arm showed an 80% reduction in vertebral fractures relative to placebo, but the trial was not powered for a direct statistical comparison between the two anabolic agents.

Bone mineral density (BMD) gains were rapid. Lumbar spine BMD increased by 9.2% with abaloparatide versus 0.5% with placebo at 18 months [4]. Total hip BMD rose by 3.4%, a particularly meaningful result because hip BMD gains tend to be modest with most osteoporosis therapies. "The speed of BMD accrual at the hip with abaloparatide was notable," observed Dr. Felicia Cosman, lead investigator on the ACTIVExtend extension study, "and may reflect its preferential activation of the modeling-based bone formation pathway" [5].

ACTIVExtend: What Happens After Abaloparatide?

Stopping an anabolic agent without follow-up antiresorptive therapy leads to rapid bone loss. The ACTIVExtend study addressed this by transitioning 1,139 women from the ACTIVE trial onto alendronate 70 mg weekly for an additional 24 months [5].

The results confirmed that sequential therapy preserves and extends the gains from the anabolic phase. Women who received abaloparatide followed by alendronate achieved a cumulative lumbar spine BMD increase of 12.8% from original baseline over 43 months, compared to 5.5% in women who received placebo followed by alendronate [5]. Total hip BMD reached a net gain of 5.5% in the abaloparatide-to-alendronate group versus 1.4% in the placebo-to-alendronate group.

Fracture protection also endured. The cumulative incidence of new vertebral fractures over the full 43-month period was 0.9% in the abaloparatide sequence group versus 5.6% in the placebo sequence group, representing an 84% relative risk reduction [5]. These data are the foundation of current clinical practice: prescribe an anabolic agent first, then consolidate with a bisphosphonate.

How Abaloparatide Compares to Teriparatide (Forteo)

Both abaloparatide and teriparatide are injectable anabolic agents given daily for a limited treatment window. The ACTIVE trial placed them side by side, though the comparison to teriparatide was open-label and not powered for superiority testing.

Vertebral fracture rates were similar. New vertebral fractures occurred in 0.58% of the abaloparatide group and 0.84% of the teriparatide group at 18 months, with no statistically significant difference [4]. Abaloparatide produced numerically greater BMD gains at the total hip (3.4% vs 2.0%) and femoral neck (2.9% vs 1.7%), and the hip differences were statistically significant (P<0.05).

The side effect profiles differ in a clinically relevant way. Hypercalcemia (serum calcium above 10.5 mg/dL) occurred in 3.4% of patients on abaloparatide versus 6.4% on teriparatide [4]. Nausea was more common with abaloparatide (8.3% vs 5.4%), while teriparatide caused more dizziness. The Endocrine Society's 2020 clinical practice guideline considers both agents appropriate first-line anabolic options for patients at very high fracture risk, without expressing a preference for one over the other [6].

Teriparatide carries the same boxed warning about osteosarcoma observed in rats. Neither drug has a confirmed causal link to osteosarcoma in humans after more than 20 years of combined post-marketing surveillance [3].

Bisphosphonates: The Antiresorptive Backbone

Bisphosphonates remain the most widely prescribed class of osteoporosis medications, and understanding them is necessary context for knowing where abaloparatide fits. Four bisphosphonates dominate clinical use.

Alendronate (Fosamax) is the most commonly prescribed oral bisphosphonate. Dosed at 70 mg once weekly (or 10 mg daily), it reduced vertebral fractures by 44% and hip fractures by 51% over three years in the Fracture Intervention Trial (FIT; N=2,027) [7]. It is generic, costing as little as $4 to $15 per month. Alendronate is also the default sequencing agent after anabolic therapy, as demonstrated in ACTIVExtend.

Risedronate (Actonel) offers similar efficacy. The VERT-NA trial (N=2,458) showed a 41% reduction in new vertebral fractures over three years [8]. Risedronate is available in daily (5 mg), weekly (35 mg), and monthly (150 mg) formulations. Some clinicians prefer it for patients who experience more GI irritation with alendronate, though head-to-head GI comparisons are limited.

Ibandronate (Boniva) is the only bisphosphonate with a monthly oral option (150 mg) or quarterly intravenous infusion (3 mg). The BONE trial (N=2,946) demonstrated a 62% reduction in vertebral fractures at three years [9]. A limitation: ibandronate lacks strong data for nonvertebral and hip fracture reduction, which is why guidelines generally rank it below alendronate and risedronate for patients at high hip fracture risk.

Zoledronic acid (Reclast) is the most potent bisphosphonate, given as a single 5 mg IV infusion once yearly. The HORIZON-PFT trial (N=7,765) showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over three years [10]. The annual dosing eliminates oral adherence issues entirely. Zoledronic acid is the preferred sequencing agent when oral bisphosphonate adherence is a concern or when denosumab discontinuation requires a strong antiresorptive bridge.

Anabolic-First Sequencing: Why It Matters

For decades, bisphosphonates were prescribed as first-line therapy. That approach is changing. The 2020 Endocrine Society guideline recommends that patients at very high fracture risk (defined as recent fracture, T-score <-3.0, or high FRAX score) start with an anabolic agent rather than a bisphosphonate [6].

The rationale comes from sequencing studies. The DATA-Switch trial compared denosumab-to-teriparatide versus teriparatide-to-denosumab sequences and found that starting with the anabolic agent produced significantly greater BMD gains at the spine and hip over four years [11]. The ACTIVExtend data for abaloparatide-to-alendronate further reinforced this principle.

Starting with a bisphosphonate creates a biological ceiling. Bisphosphonates suppress bone turnover, and when an anabolic agent is given afterward, the remodeling response is blunted for the first 6 to 12 months. "You cannot build on a foundation of suppressed turnover as effectively as you can build on a treatment-naive skeleton," noted Dr. Benjamin Leder of Massachusetts General Hospital, the principal investigator of the DATA studies [11]. Starting with abaloparatide or teriparatide, then locking in gains with alendronate or zoledronic acid, produces the highest peak BMD a patient is likely to achieve pharmacologically.

Side Effects and Safety Profile

The most common adverse event with abaloparatide is injection-site erythema, reported in about 14% of patients in the ACTIVE trial [4]. Other frequent reactions include dizziness (10%), nausea (8%), headache (8%), palpitations (5%), and fatigue (3%).

Orthostatic hypotension can occur within four hours of injection. Patients are advised to sit or lie down if they feel lightheaded. This effect tends to diminish after the first few doses. Heart rate increases of 1 to 2 beats per minute have been documented, though no increase in cardiovascular events was observed in ACTIVE [4].

The boxed warning for osteosarcoma deserves context. In preclinical studies, rats given abaloparatide for nearly their entire lifespan developed osteosarcoma at high doses. Rats are uniquely susceptible to this tumor type because they maintain open growth plates throughout life, unlike humans. A 15-year post-marketing surveillance study of teriparatide (which carries the same warning) found no increased osteosarcoma incidence in humans compared to background rates [3]. The warning remains on the label as a precaution, and abaloparatide is contraindicated in patients with unexplained elevations of alkaline phosphatase, Paget's disease, open epiphyses, prior radiation to the skeleton, pre-existing hypercalcemia, or bone metastases.

Who Is a Candidate for Abaloparatide?

The strongest candidates are postmenopausal women at very high fracture risk. The Endocrine Society defines this as patients with a T-score of -2.5 or below who also have one or more of the following: a recent osteoporotic fracture (within the past 12 months), a T-score at or below -3.0, multiple vertebral fractures, or a 10-year FRAX probability of major osteoporotic fracture exceeding 30% [6].

Abaloparatide is not currently FDA-approved for men with osteoporosis or for glucocorticoid-induced osteoporosis, though off-label use occurs. A phase 3 trial (ATOM; NCT03512262) evaluated a transdermal abaloparatide patch in men with osteoporosis, but the transdermal delivery system did not advance to approval [12].

Patients who have failed or are intolerant of bisphosphonates are also candidates. A woman who sustains a new fracture while on alendronate, for example, should be considered for anabolic therapy rather than simply switching to another antiresorptive.

Cost, Insurance, and Access

Abaloparatide carries a list price of roughly $1,900 to $2,200 per month. The manufacturer (Radius Health, now part of Ipsen) offers a patient savings program that can reduce out-of-pocket costs to as low as $0 for commercially insured patients, though copay assistance programs do not apply to Medicare Part D beneficiaries [1].

Medicare Part D covers abaloparatide under the specialty tier, typically requiring prior authorization and documentation of high fracture risk or bisphosphonate failure. Step therapy requirements vary by plan; some insurers mandate a trial of at least one bisphosphonate (usually alendronate or zoledronic acid) before approving an anabolic agent. The appeals process should include the 2020 Endocrine Society guideline language supporting anabolic-first therapy for very high-risk patients.

For comparison, generic alendronate costs $4 to $15 per month, generic risedronate runs $15 to $60 per month, and zoledronic acid infusion costs approximately $200 to $500 per annual dose (excluding facility fees) [7][10]. The cost difference between anabolic and antiresorptive agents is substantial, but the fracture reduction data support the investment for appropriately selected patients.

Practical Dosing and Administration

Each Tymlos pen contains 30 daily doses of 80 mcg. The pen does not require reconstitution. Patients remove the pen from the refrigerator, attach a new needle, prime before first use, inject subcutaneously into the abdomen, and return the pen to the refrigerator. The injection is given at approximately the same time each day.

Lab monitoring is straightforward. Check serum calcium at baseline and periodically during treatment. Patients should have adequate calcium intake (1,000 to 1 to 200 mg daily from diet and supplements combined) and maintain a 25-hydroxyvitamin D level of 30 ng/mL or above before starting therapy [6]. A DXA scan at 12 months can confirm BMD response, though treatment decisions should not rely solely on DXA changes during the anabolic phase because bone quality improvements may precede measurable density gains.

After completing the abaloparatide course, transition to an antiresorptive within one month. Delaying the transition allows rapid resorption of newly formed bone. The ACTIVExtend protocol used alendronate 70 mg weekly, but zoledronic acid 5 mg IV annually is an acceptable alternative, particularly for patients with adherence concerns or GI intolerance to oral bisphosphonates [5][10].